Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500 ...
Enara Bio, a pioneer in Dark Antigen(R) discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual ...
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...
Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX Therapeutics six years after the two companies ...
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication ...
Morning Overview on MSN
Researchers map real-time signals that trigger T cell activation
A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...
A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results